Autopsy report · NCT02372695

Effect of Paricalcitol Over Vessel Wall

“Protocol showed to be inappropriate for the evaluation of the selected patients”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months after it had already started.
• Ran for about 10 months before it stopped.
• 50 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Effice Servicios Para la Investigacion S.L.

Sponsor type

Industry

Conditions

Nephropathy

Interventions

Paricalcitol

Participants

50

Trials that died the same way

• Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis
  “Lack of patients compatible with the protocol´s criteria” (68% match in meaning)
• Optimized Caloric-proteic Nutrition in Septic and Septic Shock Patients
  “The protocol was modified substantially and will be resubmitted to Clinical Trial” (61% match in meaning)
• Saracatinib in Treating Patients With Prostate Cancer
  “Per protocol, study was terminated due to low rate of randomized patients.” (61% match in meaning)
• Impact of Current Smoking in the Tolerance of Bronchoscopy
  “the physician responsable for this protocol left our hospital” (57% match in meaning)
• Improving Medication Adherence in Post-ACS Patients
  “This was a dosing study to determine acceptability. Participants found protocol burdensome and so we terminated.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.